ENHANCED LYTIC EFFICACY OF MULTIPLE BOLUS INJECTIONS OF TISSUE PLASMINOGEN-ACTIVATOR IN DOGS

被引:7
|
作者
KLABUNDE, RE [1 ]
BURKE, SE [1 ]
HENKIN, J [1 ]
机构
[1] ABBOTT LABS,DEPT THROMBOLYT VENTURE D48R,ABBOTT PK,IL 60064
关键词
Alpha-2-Antiplasmin; Clot Lysis; Fibrinogen; Fibrinolysis; Thrombolysis; Tissue Plasminogen Activator;
D O I
10.1016/0049-3848(91)90256-V
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to compare the lytic efficacy of tissue plasminogen activator (tPA) following different dosing regimens. Radiolabelled clots from dog whole blood were inserted into an extracorporeal jugular loop in anesthetized dogs. Clot size (counts/min) was continuously recorded, tPA was administered as a single 1 min bolus of 0.4 mg/kg, as four multiple bolus injections of 0.1 mg/kg each at 30 min intervals, or as an initial bolus (0.04 mg/kg) followed by a 30 min infusion of 0.36 mg/kg (10%/90%, bolus/infusion). Multiple injections of the same total dose of tPA resulted in 76% and 51% greater clot lysis than single bolus injection or bolus/infusion regimen, respectively, measured 120 min after initial dosing. There were no differences in fibrinogen, plasminogen or alpha-2-antiplasmin between the different treatment groups at 120 min. © 1990.
引用
收藏
页码:511 / 517
页数:7
相关论文
共 50 条
  • [31] DIFFERENTIAL EFFECT OF PLATELETS ON PLASMINOGEN ACTIVATION BY TISSUE PLASMINOGEN-ACTIVATOR, UROKINASE, AND STREPTOKINASE
    GAO, SW
    MORSER, J
    MCLEAN, K
    SHUMAN, MA
    THROMBOSIS RESEARCH, 1990, 58 (04) : 421 - 433
  • [32] Individual Lytic Efficacy of Recombinant Tissue Plasminogen Activator in an In Vitro Human Clot Model: Rate of "Nonresponse"
    Meunier, Jason M.
    Wenker, Evan
    Lindsell, Christopher J.
    Shaw, George J.
    ACADEMIC EMERGENCY MEDICINE, 2013, 20 (05) : 449 - 455
  • [33] ACUTE REDUCTION OF LIPOPROTEIN(A) BY TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    HEGELE, RA
    FREEMAN, MR
    LANGER, A
    CONNELLY, PW
    ARMSTRONG, PW
    CIRCULATION, 1992, 85 (06) : 2034 - 2038
  • [34] INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR FOR THE TREATMENT OF ACUTE THROMBOEMBOLIC ISCHEMIA
    HENNERICI, M
    HACKE, W
    VONKUMMER, R
    HORNIG, C
    ZANGEMEISTER, W
    CEREBROVASCULAR DISEASES, 1991, 1 : 124 - 128
  • [35] TISSUE PLASMINOGEN-ACTIVATOR AND CARDIOPULMONARY BYPASS FOR MASSIVE PULMONARY EMBOLUS
    FRIZELLE, FA
    MASSEY, R
    FEINT, JA
    XABREGAS, AA
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1991, 61 (02): : 151 - 153
  • [36] THROMBOLYTIC EFFECT OF TISSUE PLASMINOGEN-ACTIVATOR IN A CEREBRAL EMBOLIC MODEL
    KIMATA, H
    NAKAJIMA, K
    SUZUKI, H
    KOIDE, T
    NARITA, T
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1991, 14 (07): : 399 - 406
  • [37] IMMUNOLOCALIZATION OF TISSUE PLASMINOGEN-ACTIVATOR IN THE DIABETIC AND NONDIABETIC RETINA AND CHOROID
    LUTTY, GA
    IKEDA, K
    CHANDLER, C
    MCLEOD, DS
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1991, 32 (02) : 237 - 245
  • [38] NORMAL TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN PLASMA FROM PATIENTS WITH TYPE-1 DIABETES-MELLITUS
    VICARI, AM
    DANGELO, SV
    TESTA, S
    COMI, G
    GALARDI, G
    ORSI, E
    DANGELO, A
    HORMONE AND METABOLIC RESEARCH, 1992, 24 (11) : 516 - 519
  • [40] TREATMENT OF EXPERIMENTAL SUPRACHOROIDAL HEMORRHAGE WITH INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR
    LIU, JC
    PEYMAN, GA
    ONCEL, M
    INTERNATIONAL OPHTHALMOLOGY, 1990, 14 (04) : 267 - 270